What are the common side effects of olezarsen?

Olezarsen is a new type of antisense oligonucleotide drug, mainly used to treat severe hypertriglyceridemia caused by lipoprotein lipase dysfunction such as familial chylomicronemia syndrome (FCS). As a treatment targeting the APOC3 gene, Olezasen has demonstrated significant clinical efficacy in regulating lipid metabolism. However, like all drugs, while Olezasen brings therapeutic effects, it may also cause a series of side effects, which requires more attention especially during long-term use.

1. Injection site related reactions are relatively common

Olezacen is usually administered as a subcutaneous injection, so injection site reactions are one of its most common adverse effects. According to clinical trial data, some patients will experience reactions such as local redness and swelling, pain, itching, rash, induration or ecchymosis after injection. Most of these side effects are mild to moderate and usually do not affect the continued treatment, but patients still need to closely observe the development of local reactions. If the reaction worsens, it may be necessary to suspend administration and ask a doctor for evaluation.

2. Abnormal liver function indicators require focused monitoring

The mechanism by which Olezasen affects lipid metabolism may put a certain burden on the liver. In clinical trials, it was observed that some patients experienced an increase in liver function indicators during use, especially a slight increase in the levels of transaminases (ALT, AST). This suggests that patients need regular liver function monitoring while taking Olezasen, especially patients with liver disease or long-term use of this drug should pay special attention. Once the liver enzymes rise more than 3 times the upper limit of normal, the drug should be suspended and evaluated to see if it is related to olazasen.

3. Changes in platelet count and its risks

It has been reported that some antisense oligonucleotide drugs may cause thrombocytopenia. Although the incidence of such adverse events in the current clinical study of Olezasen is low, this risk cannot be completely ruled out in long-term use. For this reason, it is recommended to regularly monitor blood routine, especially platelet count, during treatment. If an abnormal downward trend is found, the dose should be adjusted in time or use should be suspended, and subsequent treatment plans should be determined according to the doctor's advice.

4. Other manifestations of dyslipidemia

While Olezasen significantly reduces triglyceride levels, it may also have a certain impact on other lipid indicators (such asHDL-C and LDL-C). Some patients have experienced an increase in HDL-C (high-density lipoprotein cholesterol) during use. Although it is generally considered beneficial, extreme increases should also be noted to see if they are accompanied by other metabolic abnormalities. In addition, individual patients may experience an increase in LDL-C, which should be evaluated and intervened in conjunction with the overall lipid profile.

5. Flu-like symptoms and fatigue

In some clinical trials, individual patients reported mild general discomfort, including fatigue, weakness, fever, chills, muscle aches, etc. These symptoms are similar to flu-like reactions. The mechanism may be related to the immune response or the mild inflammatory response triggered by the drug itself, which usually resolves on its own within a short period of time. If symptoms continue to worsen, you need to seek medical attention promptly to investigate other causes.

6. Gastrointestinal discomfort reaction

Some users of Olezacen report that they may experience mild gastrointestinal discomfort, such as nausea, bloating, diarrhea or loss of appetite during treatment. Such symptoms are generally related to the systemic effects of drugs. They usually appear more frequently in the early stages of treatment and may gradually ease in the later stages as the body adapts. If it continues to affect eating or weight, it is recommended to communicate with your doctor whether the treatment strategy needs to be adjusted.

7. Immune-related adverse reactions

Although current research has not found that olazasen causes serious immune system abnormalities, antisense oligonucleotide drugs may theoretically activate non-specific immune responses or produce anti-drug antibodies. Therefore, during long-term medication, if a patient develops suspicious immune reactions such as repeated fever, rash, swollen lymph nodes, etc., attention should be paid to it and timely medical treatment should be sought.

8. Safety issues for special groups of people

Experience in its use in pregnant women, lactating women, children, and patients with severe renal insufficiency is limited, and most current clinical trials are still focused on the adult population. Therefore, the use of olazasen in these special groups should be done with extreme caution, and the decision whether to use the drug must be made after the doctor evaluates the benefits and risks.

As a new drug for the targeted treatment of hypertriglyceridemia, Olezasen has remarkable efficacy, but its side effects cannot be ignored. Generally speaking, most of its adverse reactions are mild to moderate, controllable, and will not cause serious problems in most patients. However, patients are still required to undergo regular blood tests as directed by their doctor during use, paying particular attention to injection site reactions, liver function, platelet count, and general discomfort.

For clinicians, possible adverse reactions should be fully explained to patients before medication, and an individualized monitoring plan should be developed. For patients, maintaining a good lifestyle, monitoring physical signs on a regular basis, and finding a balance between drug treatment and health management are the keys to improving efficacy and reducing the risk of side effects.

Reference materials:https://www.drugs.com/